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What is this patient’s prognosis regarding graft rejection?
Do patients using a particular drug live longer than those
not using it? How does this co-morbidity affect access to
transplantation? To answer this type of questions one needs
to perform survival analysis. This paper focuses on the
Kaplan–Meier method, the most popular method used for
survival analysis. It makes it possible to calculate the
incidence rate of events like recovery of renal function,
myocardial infarction or death by using information from all
subjects at risk for these events. It explains how the method
works, how survival probabilities are calculated, survival data
can be summarized and survival in groups can be compared
using the logrank test for hypothesis testing. In addition, it
provides some guidance regarding the presentation of
survival plots. Finally, it discusses the limitations of the
Kaplan–Meier method and refers to other methods that
better serve additional purposes.
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As one of the aims of physicians is to prevent and cure their
patients from disabling and life-threatening diseases, a
considerable part of the studies in the area of medicine deal
with survival. Each month in every medical journal the
technique of survival analysis is used both in prognostic and
in therapeutic studies to estimate and interpret survival, to
compare it between groups, and to assess the relationship of
explanatory variables with survival time. Therefore, typical
examples of publications using survival analysis are a report
providing details on the prognosis of elderly transplant
recipients regarding their estimated 5-year probability of
graft rejection,1 a publication on the difference in mortality
between diabetic patients using or not using angiotensin-
converting enzyme inhibitors2 and an article describing the
impact of comorbidity on access to transplantation in dialysis
patients.3
The primary aim of survival analysis is the modeling and
analysis of ‘time-to-event’ data; that is, data that have as an
end point the time when an event occurs. In this respect,
events are not limited to death but may include all kinds of
‘positive’ or ‘negative’ events like myocardial infarction,
recovery of renal function, first renal transplant, graft failure,
or time to discharge from hospital. In addition to these
‘single’ end points, an increasing number of studies examine
the incidence of a combined or composite end point, which
can merge a variety of outcomes in one group. For example,
the 4-D study used ‘death from cardiac causes, nonfatal
myocardial infarction, and stroke’ as their primary outcome,4
whereas the CREATE trial chose to study the incidence of a
‘composite of eight cardiovascular events’.5 Using combined
end points, one addresses event-free survival, an important
criterion in therapy evaluation. It is customary to talk about
survival analysis and survival data, regardless of the nature of
the event. Still, by far the most frequently used event in
survival analysis is overall mortality.
A clinical example of when questions related to survival
are raised is the following. Suppose you consider starting the
preparation of dialysis in the near future in a 70-year-old
patient with ESRD with a myocardial infarction in his
medical history. While preparing the discussion of this topic
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with your patient, you ask yourself questions like ‘what is the
probability of dialysis patients in this age category in my
country to be alive for another 2 or 5 years?’, ‘how is the
prognosis in this type of patients being affected by ischemic
heart disease?’ and ‘what is the experience with the use of
either hemodialysis or peritoneal dialysis in similar patient
groups in terms of patient survival?’. A search through the
literature in nephrology journals and renal registry reports
will help you to answer these questions. All of them will have
made use of survival analysis. This article provides a first
introduction to those analysis techniques.
EVENTS VERSUS CENSORED DATA
The distinguishing feature of survival data is that at the end
of the follow-up period, the event will probably not have
occurred for all patients. For these patients, survival time is
said to be censored. We do not know when or whether such a
patient will experience the event of interest, but we know
only that he or she has not done so by the end of the
observation period.6 Censoring may also occur for other
reasons. A patient may be lost to follow-up during the study
or may experience a ‘competing’ event as a result of which
further follow-up is impossible.6 For example, patients being
followed for myocardial infarction on dialysis may die of a
malignancy. Other cases of censoring are included in the
following example on the survival of RRT patients.
Example 1. Survival time on RRT: events and censored
observations
Incident RRT patients in the ERA-EDTA Registry were included
in an analysis of patient survival on renal replacement therapy
(RRT).1 Like in most survival studies, patients were recruited
over a period of time (1996–2000, the inclusion period) and
they were observed up to a specific date (31 December 2005, the
end of the follow-up period). During this period, the event of
interest was ‘death while on RRT’, whereas censoring took place
at recovery of renal function, loss to follow-up, and at 31
December 2005.
Figure 1 shows the times that eight of the patients from
this cohort were at risk of death on RRT. Over the period,
there were five events and three censored observations. Here,
one can see the analogy with the concept of incidence rate
that was explained in a previous paper.7 In that article, it was
outlined that incidence rate (synonym: hazard) is the ratio of
the number of subjects developing disease (or other health
outcome) to the time at risk for disease and that it is an
instantaneous concept, like speed. In example 1, the
investigators studied the incidence rate (hazard) of death,
‘the speed of dying’, as the number of deaths was related to
the time at risk of death on RRT.
ASSUMPTIONS RELATED TO CENSORING
There are some assumptions related to the use of censoring.8
The two most important ones will be discussed here. First, it
is assumed that at any time, patients who are censored have
the same survival prospects as those who continue to be
followed. This assumption cannot easily be tested. In the
survival of dialysis patients, for example, it is customary to
censor the survival time of a patient at the time of
transplantation, because at that time, the patient is no longer
at risk of death on dialysis. However, we all know that dialysis
patients who are placed on the waiting list for transplantation
are healthier than those who are not.9 Therefore, using
censoring for transplantation while studying the survival on
dialysis is needed, because of the change in treatment, but it
is in this case probably that this first assumption for the use
of censoring is not fully fulfilled. Secondly, survival
probabilities are assumed to be the same for subjects
recruited early and late in the study. This assumption may
be tested, for example, by splitting a cohort of patients in
those who were recruited early and those recruited late and
checking if their survival curves are different.
Using survival data, investigators often wish to estimate
the probability of a patient surviving for a given period like 1
or 2 years. In addition, they are also interested to compare
the survival of different groups. The next paragraph will
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Figure 1 | Survival times of eight patients at risk of death on RRT. The inclusion period was 1996–2000, whereas follow-up was ended
on 31 December 2005.
Kidney International (2008) 74, 560–565 561
KJ Jager et al.: The analysis of survival data a b c o f e p i d e m i o l o g y
elaborate on the method that is most frequently used to
calculate survival probabilities, the Kaplan–Meier method.
DISPLAYING SURVIVAL DATA
A sample of 50 patients from a study on diabetes10 is used to
illustrate the application of the Kaplan–Meier method.
Example 2. Survival probability in RRT patients for ESRD
due to diabetes mellitus and other causes
In a sample of 50 RRT patients taken from a study on diabetes
mellitus,10 survival time started running at the moment a
patient was included in the study, in this case at the start of
RRT. Patients were followed until death or censoring. The
survival probability was calculated using the Kaplan–Meier
method. Subsequently, the survival of patients with ESRD due
to diabetes mellitus was compared with the survival of those
with ESRD due to other causes.
Before analysis, the observed survival times were first
sorted in ascending order, starting with the patient with the
shortest survival time. This resulted in Table 1 showing the
patient deaths and the censored observations over the first
1708 days. By then, considering time in many small intervals,
it becomes possible to calculate the probability of surviving a
given day. At the start of the study, all 50 patients were alive,
so the proportion surviving and the cumulative survival
(synonym: cumulative proportion surviving) both were 1.00.
When the first patient died on day 34 after the start of
RRT, the proportion surviving on that day was 49/
50¼ 0.9800¼ 98%. To calculate the cumulative survival, this
proportion surviving of 0.9800 was multiplied by the 1.0
cumulative survival from the previous step resulting in a
cumulative survival dropping that day to 0.9800. Then, when
the second patient died at day 35, the proportion surviving
on that day was 48/49¼ 0.9796. To obtain the cumulative
survival at day 35, again, this proportion was multiplied by
the 0.9800 cumulative survival from the previous step, which
resulted in a cumulative survival dropping that day to 0.9600.
Along the same lines, cumulative survival on day 44 dropped
to 0.9400. On day 57, however, a patient was withdrawn alive
from the study, because his follow-up time was censored at
the end of the study period. The proportion surviving that
day was 47/47¼ 1.00, as this patient did not die but was
Table 1 | Cumulative survival table in 50 RRT patients
Time in
days
Number
at risk Deaths
Withdrawn alive
(censored)
Proportion surviving
on this day
Cumulative
survivala
Cumulative mortality
(1cumulative survival)
0 50 0 0 1.00 1.00 0
34 50 1 0 49/50=0.9800 0.9800 0.0200
35 49 1 0 48/49=0.9796 0.9600 0.0400
44 48 1 0 47/48=0.9792 0.9400 0.0600
57 47 0 1 1 0.9400 0.0600
75 46 1 0 45/46=0.9783 0.9196 0.0804
159 45 1 0 44/45=0.9778 0.8991 0.1009
192 44 0 1 1 0.8991 0.1009
199 43 1 0 42/43=0.9767 0.8782 0.1218
206 42 0 1 1 0.8782 0.1218
232 41 1 0 40/41=0.9756 0.8568 0.1432
316 40 1 0 39/40=0.9750 0.8354 0.1646
319 39 0 1 1 0.8354 0.1646
344 38 1 0 37/38=0.9737 0.8134 0.1866
363 37 1 0 36/37=0.9730 0.7914 0.2086
365 36 0 1 1 0.7914 0.2086
398 35 0 1 1 0.7914 0.2086
410 34 1 0 33/34=0.9706 0.7681 0.2319
491 33 1 0 32/33=0.9697 0.7449 0.2551
552 32 1 0 31/32=0.9688 0.7216 0.2784
575 31 0 1 1 0.7216 0.2784
628 30 0 1 1 0.7216 0.2784
728 29 1 0 28/29=0.9655 0.6967 0.3033
791 28 0 1 1 0.6967 0.3033
824 27 1 0 26/27=0.9630 0.6709 0.3291
896 26 0 1 1 0.6709 0.3291
954 25 1 0 24/25=0.9600 0.6441 0.3559
1115 24 0 1 1 0.6441 0.3559
1142 23 1 0 22/23=0.9565 0.6161 0.3839
1178 22 1 0 21/22=0.9545 0.5881 0.4119
1186 21 1 0 20/21=0.9524 0.5601 0.4399
1211 20 0 1 1 0.5601 0.4399
1323 19 0 1 1 0.5601 0.4399
1650 18 1 0 17/18=0.9444 0.5289 0.4711
1708 17 1 0 16/17=0.9412 0.4978 0.5022
aCumulative survival is calculated: proportion surviving on this day cumulative survival over the previous period.
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withdrawn alive from the study. As a result, the cumulative
survival did not drop that day but remained unchanged at
0.9400. This example shows that cumulative survival is a
probability of surviving the next period multiplied by the
probability of having survived the previous period. Secondly,
the example shows that all subjects at risk (also those not
experiencing the event during the observation period) can
contribute survival time to the denominator of the incidence
rate. Finally, it demonstrates that by censoring, one is able to
reduce the number of persons alive without affecting the
cumulative survival. The same data were used to construct
the survival curve of these 50 patients, which is shown in
the upper panel of Figure 2. The figure displays visually
that cumulative survival drops with every death, whereas
it remains unchanged with every censored observation
(indicated by the plus signs).
REPORTING SURVIVAL BASICS
Survival can be summarized by quoting survival probabi-
lities. The 1-, 2-, and 5-year cumulative survival of the
patients in example 2 were 79, 70, and 40%. An alternative
way to summarize survival is to quote the median survival.
The median survival is that point in time from the time of
inclusion when the cumulative survival drops below 50%. It
is not related to the number of deaths or to the number of
subjects that is still at risk of death. In example 2, including
50 patients, the median survival time was 1708 days, whereas
the total number of deaths up on that day was 22 and the
number of patients still at risk of death was 16. In clinical
trials, median survival time is a way to measure the
effectiveness of a treatment.
In general, investigators use median survival rather than
mean survival. There are a number of reasons for this. The
first one is that samples of survival times are mostly highly
skewed and in those cases the median is generally a better
measure of central location than the mean. A second reason
is that in survival analysis, one makes use of censoring. As we
explained earlier, one does not know when or whether such a
person will experience the event of interest, but one knows
only that he or she has not done so by the end of the
observation period. This complicates the calculation of the
mean. Finally, even in cases where there is no censoring, to
calculate a mean, one would need to wait until all persons
reached the event of interest, and this may require quite a
long period. For these reasons, it is simpler to use median
survival, as this is completely defined once the survival curve
descends to 50%.
COMPARING SURVIVAL BETWEEN GROUPS
When comparing survival between different groups, one
could compare the cumulative survival at some specific time.
The weakness of this approach is, however, that it does not
provide a comparison of the total survival experience of the
two groups, but rather gives a comparison at one arbitrary
time point. To prevent this problem, one may use the logrank
test, the most popular method of comparing the survival of
groups, which takes the whole follow-up period into
account.11 The log-rank test addresses the hypothesis that
there are no differences between the populations being
studied in the probability of an event at any time point. The
test is based on the same assumptions as the Kaplan–Meier
method.
The lower panel of Figure 2 that was derived from
example 2 displays the survival curves of the patients with
ESRD due to diabetes mellitus and those with ESRD due to
other causes. These curves provide a means of assessing
visually whether survival was different for these subgroups.
When the log-rank test was used to test formally whether the
difference was statistically significant, it showed a P-value of
0.0425; therefore, also in this small sample of 50 patients, the
difference was statistically significant.
SURVIVAL PLOTS
Usually, survival plots are presented as cumulative survival
displaying the proportion of patients free of the event
declining over time. Sometimes, however, they are presented
as cumulative mortality showing the proportion of subjects
experiencing the event by time. The data from a third study12
are used to show this difference.
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Figure 2 | Cumulative survival in RRT patients. (a) overall and
(b) by cause of ESRD.
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Example 3. Survival probability in patients treated with
hemodialysis and peritoneal dialysis
In a sample of almost 1700 dialysis patients taken from a study
on the effect of comorbidity on survival,12 survival probabilities
from day 90 after the start of RRT were calculated for patients
on hemodialysis and peritoneal dialysis.
Figure 3 shows cumulative survival and cumulative
mortality plots containing the same information, but using
different ranges for the y axis. We will use these to discuss the
recommendations of Pocock et al.13 on the publication of
survival plots. These authors have a preference for survival
plots being presented upward as cumulative mortality,
especially for studies with a low event rate (lower than
30%), as in this way without using the full range of 0–1 for
the y axis (Figure 3d), it is possible to provide more detail
without the need for a break in the y axis (Figure 3c).
Secondly, they state that the number of participants that is
still at risk should be listed under the time axis and that plots
should only be extended through the period of follow-up
achieved by a reasonable proportion (10–20%) of partici-
pants. Furthermore, they recommend plots always to include
some measure of statistical uncertainty. For Kaplan–Meier
curves, this may be the P-value derived from the log-rank
test, whereas for Cox regression, hazard ratios may be
presented together with their confidence intervals. Therefore,
according to Pocock et al., Figure 3d would be the best way to
present the data in example 3.
Another matter to consider while inspecting survival plots
is how likely the outcomes are over time. The incidence rate
of an event may be high early during follow-up with a
decrease later or vice versa. In Figure 4, the follow-up in
example 3 was extended to 3 years. It shows that after 2.5
years, the difference in survival between the modalities
became smaller to disappear at 3 years. Therefore, in survival
plots, it is important to look at time-dependent effects, which
will be extensively discussed in a future article in this series.
To be able to do so, it is important to have follow-up data of
sufficient duration on an adequate sample size.
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Figure 3 | Survival plots by treatment modality. (a) Cumulative survival (y axis 0–1); (b) cumulative mortality (y axis 0–1);
(c) cumulative survival (y axis 0.75–1.0); (d) cumulative mortality (y axis 0–0.25). The numbers below the figures denote the number of
patients ‘at risk’ in each group.
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WHAT THE KAPLAN–MEIER METHOD AND THE LOG-RANK
TEST CAN AND CANNOT DO
The Kaplan–Meier method is the most popular method used
for survival analysis. Together with the log-rank test, it may
provide us with an opportunity to estimate survival
probabilities and to compare survival between groups. Most
of the time, however, one would like to do more than that. In
example 3, where the survival on hemodialysis and on
peritoneal dialysis were compared, one would have liked to
be informed on the size of any potential difference. In
addition, to make a more fair comparison between the two
dialysis modalities, one would have liked to adjust for age
and other confounding variables. However, as the log-rank
test is purely a significance test, it cannot provide an estimate
of the size of the difference between groups and a related
confidence interval. Secondly, the Kaplan–Meier method and
the log-rank test can only study the effect of one factor at the
time, and therefore they cannot be used for multivariate
analysis. For these purposes, one may use a regression
technique like the Cox proportional hazards model, which
will be described in the next article in this series.
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